

Yurasov Sergey
Form 4
July 19, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Yurasov Sergey

(Last) (First) (Middle)

C/O IMMUNE DESIGN
CORP., 1616 EASTLAKE AVE. E.,
SUITE 310

(Street)

SEATTLE, WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

IMMUNE DESIGN CORP. [IMDZ]

3. Date of Earliest Transaction
(Month/Day/Year)

07/17/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
Sr. VP, Clinic. Devel. & CMO

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
				Code	V	Amount	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction	5. Number of Derivative	6. Date Exercisable and Expiration Date	7. Title and Amount Underlying Securities
------------------------	---------------	--------------------------------------	-------------------------------	----------------	-------------------------	---	---

Edgar Filing: Yurasov Sergey - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security	any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)	(Instr. 3 and 4)				
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Rt to Buy)	\$ 7.58	07/17/2018	D		52,768		<u>(1)</u>	10/01/2025	Common Stock	52,768
Stock Option (Rt to Buy)	\$ 4.4	07/17/2018	A		35,179		<u>(3)</u>	07/17/2025	Common Stock	35,179
Stock Option (Rt to Buy)	\$ 7.58	07/17/2018	D		87,232		<u>(1)</u>	10/01/2025	Common Stock	87,232
Stock Option (Rt to Buy)	\$ 4.4	07/17/2018	A		58,155		<u>(3)</u>	07/17/2025	Common Stock	58,155
Stock Option (Rt to Buy)	\$ 5.6	07/17/2018	D		625		<u>(5)</u>	01/04/2027	Common Stock	625
Stock Option (Rt to Buy)	\$ 4.4	07/17/2018	A		417		<u>(7)</u>	07/17/2025	Common Stock	417
Stock Option (Rt to Buy)	\$ 5.6	07/17/2018	D		29,375		<u>(5)</u>	01/04/2027	Common Stock	29,375
Stock Option (Rt to Buy)	\$ 4.4	07/17/2018	A		19,584		<u>(7)</u>	07/17/2025	Common Stock	19,584

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other
 Sr. VP, Clinic. Devel. & CMO

Yurasov Sergey
C/O IMMUNE DESIGN CORP.
1616 EASTLAKE AVE. E., SUITE 310
SEATTLE, WA 98102

Signatures

/s/ Stephen R. Brady,
Attorney-In-Fact

07/19/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option provided for vesting of 1/4th of the shares underlying the option on October 1, 2017 and the remainder of the shares at a rate of 1/36th per month thereafter.

On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 52,768 shares of the issuer's

(2) common stock granted to the reporting person on October 1, 2016. In exchange, the reporting person received a replacement option, for 35,179 shares, having an exercise price of \$4.40 per share.

(3) The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018.

On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 87,232 shares of the issuer's

(4) common stock granted to the reporting person on November 1, 2016. In exchange, the reporting person received a replacement option, for 58,155 shares, having an exercise price of \$4.40 per share.

(5) The option provided for 1/4th of the shares underlying the option on January 4, 2018 and the remainder of the shares underlying the option at a rate of 1/36th per month thereafter.

On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 625 shares of the issuer's common

(6) stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 417 shares, having an exercise price of \$4.40 per share.

(7) The option vests in thirty six (36) equal consecutive monthly installments beginning on August 17, 2018.

On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 29,375 shares of the issuer's

(8) common stock granted to the reporting person on January 4, 2017. In exchange, the reporting person received a replacement option, for 19,584 shares, having an exercise price of \$4.40 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.